Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

information fournie par Boursorama •03/02/2016 à 18:00

Strasbourg, France, and Rockville, MD, U.S. February 3, 2016 – Transgene SA (Euronext: TNG) a company specializing in immunotherapies, and ABL, Inc., a contract research and manufacturing organization, today announced the purchase by ABL Europe, a wholly owned subsidiary of ABL of Transgene’s production asset situated in Illkirch, near Strasbourg. Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.

The production asset is designed and equipped to manufacture clinical lots of biophamaceuticals and vaccines using viral vectors.

ABL Europe has just received authorization by the French Agence Nationale de Sécurité du Médicament to operate a Pharmaceutical Establishment, a mandatory step to begin operations at the site. Manufacturing and other services will be provided under E.U. and U.S. GMP.

An addition to ABL’s bioproduction capabilities
This acquisition provides ABL with a European bioproduction facility up to the most stringent quality standards, which will allow it to serve the European CMO market, in addition to its already well established position in that field in the U.S. With its Rockville (MD) production unit and its new site in Illkirch, France, ABL will be a premier global CMO in the field, with the ability to significantly increase internationally client responsiveness and schedule flexibility.
...